Depyrogenated Sterile Empty Vials Global Market Report 2024

The global depyrogenated sterile empty vials market has grown strongly in recent years. It will grow from $3.52 billion in 2023 to $3.73 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth observed in the historical period can be attributed to the rise in pharmaceutical manufacturing, adherence to stringent regulatory standards, a heightened focus on drug stability and purity, an increase in contract manufacturing, the expansion of clinical trials, the introduction of high-value biologics, an increased emphasis on patient safety, and a shift towards ready-to-use components.

The global depyrogenated sterile empty vials market is expected to see strong growth in the next few years. It will grow to $4.88 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The anticipated growth in the forecast period can be attributed to a focus on advanced drug delivery systems, an increasing regulatory emphasis on container closure integrity, the rise in personalized medicine approaches, the expansion of biomanufacturing facilities, a heightened focus on sustainable packaging, the digitalization of supply chain management, and the demand for high-value oncology drugs. Major trends in the forecast period encompass the adoption of single-use technologies, advancements in biological drug development, the application of Quality by Design (QbD) approaches, the use of biodegradable and sustainable materials, increased digitalization in supply chain management, the integration of smart packaging technologies, advancements in aseptic filling technologies, and the facilitation of collaborations and partnerships in the industry.

The depyrogenated sterile empty vials market is poised for growth due to the increasing prevalence of infectious diseases worldwide. Infectious diseases caused by microorganisms such as bacteria, viruses, parasites, and fungi drive the demand for depyrogenated sterile vials used in storing injectable medications for infectious disease treatments. Moreover, these sterile vials play a crucial role in collecting laboratory samples. For example, as of March 2022, the World Health Organization (WHO) estimates 1.3 to 4.0 million annual cholera cases globally, emphasizing the role of depyrogenated sterile empty vials in healthcare. The market is anticipated to expand in response to the rising global burden of infectious diseases.

The depyrogenated sterile empty vials market is experiencing growth driven by the increasing geriatric population. Defined as individuals aged 65 and older, the elderly population relies on depyrogenated sterile empty vials to ensure medication safety and prevent infections. This is crucial in minimizing the risk of pyrogenic reactions, particularly in older individuals who may be more susceptible to adverse effects. With global projections indicating a significant rise in the elderly population, reaching 1 in 6 people aged 60 or older by 2030, and a doubling to 2.1 billion by 2050, the demand for depyrogenated sterile empty vials is set to increase in tandem with the aging population.

Technological advancements have emerged as a key trend in the depyrogenated sterile empty vials market. Leading companies in the market are actively incorporating advanced technologies into depyrogenated sterile vials to enhance quality and maintain a competitive position. Notably, Gerresheimer introduced Gx RTF injection vials with cutting-edge features, such as being made from type I borosilicate glass, meeting ISO standards, and providing flexibility in filling and sealing technologies. This trend reflects the industry's commitment to leveraging technology to meet stringent quality standards and streamline the fill-and-finish process.

Major companies in the depyrogenated sterile empty vials market are focusing on product innovation, introducing offerings like the Ready-to-Use (RTU) sterile 100 ml molded glass vials. These vials are designed to package high-value parenteral drugs in large volumes, addressing the needs of the pharmaceutical industry. SGD Pharma launched Ready-to-Use (RTU) sterile 100 ml molded glass vials, emphasizing features like glass-to-glass contact reduction for minimized particle generation, compatibility with various injectable applications, and assurance of sterility and depyrogenation. This innovation positions companies at the forefront of the market, enhancing their competitiveness.

In June 2023, ALK-Abelló, Inc., a pharmaceutical company based in Denmark known for manufacturing sterile empty vials, entered into a strategic partnership with Galenova Inc., a Canada-based pharmaceutical company. Through this collaboration, ALK-Abelló, Inc. aims to enhance its distribution network by providing dependable and high-quality glass vials to pharmacies and hospitals throughout Canada. Galenova Inc. specializes in pharmaceutical products, including the provision of depyrogenated sterile empty vials. This partnership reflects a joint effort to strengthen the supply chain and deliver essential pharmaceutical components to the Canadian healthcare system.

Major companies operating in the depyrogenated sterile empty vials market report are APG Pharma, Corning Inc., DWK Life Sciences, Nipro PharmaPackaging, Schott AG, Thermo Fisher Scientific, Gerresheimer AG, Radpharm Scientific, Stevanato Group, SGD Pharma, VWR International LLC, Merck KGaA, SiO2 Materials Science, Sigma-Aldrich, Shandong Pharmaceutical Glass Co. Ltd., Berry Global Inc., West Pharmaceutical Services Inc., Ompi Srl, AptarGroup Inc., Pacific Vial Manufacturing Inc., Adelphi Healthcare Packaging Limited, Acme Vial and Glass Company LLC, Amposan S.A., Akey Group LLC, BMT Corporation, Cangzhou Four Stars Glass Co. Ltd., Ciron Drugs & Pharmaceuticals Pvt. Ltd., Zhejiang Pharmaceutical-Packaging Co. Ltd., Verpakkingsindustrie B.V., Sisma S.p.A.

North America was the largest region in the depyrogenated sterile empty vials market in 2023. The regions covered in the depyrogenated sterile empty vials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the depyrogenated sterile empty vials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main product types of depyrogenated sterile empty vials include 2 ml, 5 ml, 10 ml, 20 ml, and those exceeding 20 ml in volume. For example, a 2 ml vial refers to a container with a volume of 2 milliliters, commonly used for injectable drug storage. These vials are available in standard and large opening variations, typically used with aluminum seals. Depyrogenated sterile empty vials come in glass and plastic packaging, serving the needs of clinical labs, compounding labs, pharmaceutical companies, contract manufacturing organizations, and distributors.

This report provides depyrogenated sterile empty vials market statistics, including depyrogenated sterile empty vials industry global market size, regional shares, competitors with a depyrogenated sterile empty vials market share, detailed depyrogenated sterile empty vials market segments, market trends and opportunities, and any further data you may need to thrive in the depyrogenated sterile empty vials industry. This depyrogenated sterile empty vials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The depyrogenated sterile empty vials market consists of sales of type I borosilicate glass, and molded and tabular glass depyrogenated sterile empty vials. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.